Telix Pharmaceuticals

Telix Pharmaceuticals EBITDA per Share

The EBITDA per Share of Telix Pharmaceuticals (TLX.AX) as of Nov 20, 2026 is 0.09 USD. In the previous year, EBITDA per Share was 0.16 USD — a change of -42.16% (lower).

EBITDA per Share

0.09USD

YoY

-42.16%

Last updated:

EBITDA per Share of Telix Pharmaceuticals is 2025 0.09 USD. EBITDA per Share of Telix Pharmaceuticals was 2024 0.16 USD. It decreases by -42.16% lower compared to the previous year.

The Telix Pharmaceuticals EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-0.09 USD
Jan 1, 2019
-0.10 USD
Jan 1, 2020
-0.12 USD
Jan 1, 2021
-0.25 USD
Jan 1, 2022
-0.17 USD
Jan 1, 2023
0.04 USD
Jan 1, 2024
0.16 USD
Jan 1, 2025
0.09 USD
The Telix Pharmaceuticals EBITDA per Share history
YEAREBITDA per ShareYoY
0.09USD-42.16%
0.16USD+316.42%
0.04USD-122.04%
-0.17USD-32.26%
-0.25USD+113.01%
-0.12USD+15.54%
-0.10USD+19.32%
-0.09USD+79.81%
-0.05USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

EBITDA per Share of Telix Pharmaceuticals is 0.09 USD in 2025.

EBITDA per Share of Telix Pharmaceuticals changed from 0.16 USD to 0.09 USD, representing a -42.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals